| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 117 | 2023 | 807 | 16.070 |
Why?
|
| Heart Failure | 111 | 2024 | 1253 | 11.040 |
Why?
|
| Heart Transplantation | 76 | 2024 | 731 | 8.390 |
Why?
|
| Hemodynamics | 32 | 2022 | 738 | 2.480 |
Why?
|
| Intra-Aortic Balloon Pumping | 13 | 2022 | 80 | 2.460 |
Why?
|
| Tricuspid Valve Insufficiency | 11 | 2023 | 116 | 2.220 |
Why?
|
| Ventricular Function, Left | 27 | 2021 | 613 | 2.010 |
Why?
|
| Middle Aged | 162 | 2022 | 26173 | 1.960 |
Why?
|
| Heart Ventricles | 22 | 2022 | 786 | 1.890 |
Why?
|
| Cardiac Surgical Procedures | 15 | 2020 | 481 | 1.860 |
Why?
|
| Retrospective Studies | 72 | 2023 | 9237 | 1.760 |
Why?
|
| Extracorporeal Membrane Oxygenation | 6 | 2022 | 191 | 1.690 |
Why?
|
| Aortic Valve Insufficiency | 13 | 2021 | 132 | 1.660 |
Why?
|
| Subclavian Artery | 5 | 2016 | 43 | 1.650 |
Why?
|
| Male | 174 | 2022 | 42705 | 1.640 |
Why?
|
| Humans | 245 | 2024 | 90014 | 1.630 |
Why?
|
| Tissue Donors | 20 | 2024 | 505 | 1.500 |
Why?
|
| Tricuspid Valve | 10 | 2023 | 99 | 1.490 |
Why?
|
| Aged | 103 | 2022 | 19272 | 1.480 |
Why?
|
| Female | 160 | 2022 | 46617 | 1.480 |
Why?
|
| Tobacco Smoking | 2 | 2020 | 29 | 1.380 |
Why?
|
| Treatment Outcome | 55 | 2023 | 8292 | 1.370 |
Why?
|
| Cardiac Catheterization | 15 | 2020 | 307 | 1.340 |
Why?
|
| Prosthesis Implantation | 10 | 2020 | 129 | 1.320 |
Why?
|
| Postoperative Complications | 22 | 2022 | 2316 | 1.310 |
Why?
|
| Heart Valve Prosthesis Implantation | 8 | 2023 | 179 | 1.310 |
Why?
|
| Thrombosis | 9 | 2021 | 302 | 1.230 |
Why?
|
| Reoperation | 11 | 2021 | 605 | 1.230 |
Why?
|
| Counterpulsation | 5 | 2020 | 21 | 1.200 |
Why?
|
| Heart Diseases | 6 | 2015 | 302 | 1.180 |
Why?
|
| Organ Preservation | 11 | 2024 | 120 | 1.110 |
Why?
|
| Echocardiography | 18 | 2020 | 944 | 1.100 |
Why?
|
| Pulmonary Wedge Pressure | 11 | 2021 | 113 | 1.100 |
Why?
|
| Echocardiography, Transesophageal | 17 | 2016 | 348 | 1.060 |
Why?
|
| Echocardiography, Three-Dimensional | 15 | 2021 | 518 | 1.060 |
Why?
|
| Heart | 18 | 2023 | 578 | 1.060 |
Why?
|
| Liver Transplantation | 8 | 2023 | 1175 | 1.030 |
Why?
|
| Cardiac Output | 8 | 2022 | 155 | 0.960 |
Why?
|
| Defibrillators, Implantable | 5 | 2021 | 146 | 0.940 |
Why?
|
| Gastrointestinal Hemorrhage | 8 | 2020 | 239 | 0.940 |
Why?
|
| Jehovah's Witnesses | 4 | 2020 | 20 | 0.930 |
Why?
|
| Coronary Artery Bypass | 8 | 2020 | 236 | 0.930 |
Why?
|
| Adult | 83 | 2023 | 26836 | 0.890 |
Why?
|
| Mitral Valve Insufficiency | 7 | 2016 | 196 | 0.880 |
Why?
|
| Myocardium | 16 | 2023 | 573 | 0.860 |
Why?
|
| Intraoperative Care | 4 | 2020 | 85 | 0.860 |
Why?
|
| Prospective Studies | 40 | 2021 | 4329 | 0.820 |
Why?
|
| Mitral Valve | 9 | 2020 | 264 | 0.820 |
Why?
|
| Cannula | 8 | 2020 | 50 | 0.800 |
Why?
|
| Incidence | 14 | 2021 | 1604 | 0.790 |
Why?
|
| Global Health | 2 | 2020 | 193 | 0.790 |
Why?
|
| Sepsis | 3 | 2020 | 329 | 0.780 |
Why?
|
| Prosthesis Design | 17 | 2023 | 300 | 0.770 |
Why?
|
| Follow-Up Studies | 28 | 2021 | 3684 | 0.770 |
Why?
|
| Stroke | 11 | 2020 | 994 | 0.770 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2020 | 56 | 0.760 |
Why?
|
| Hemorrhage | 6 | 2018 | 287 | 0.750 |
Why?
|
| Ventricular Dysfunction | 2 | 2020 | 28 | 0.750 |
Why?
|
| Plasma Volume | 1 | 2020 | 5 | 0.740 |
Why?
|
| Organ Preservation Solutions | 8 | 2010 | 31 | 0.720 |
Why?
|
| Echocardiography, Doppler | 10 | 2020 | 187 | 0.710 |
Why?
|
| Time Factors | 35 | 2021 | 5361 | 0.700 |
Why?
|
| Aortic Valve | 11 | 2023 | 246 | 0.690 |
Why?
|
| Serum Albumin | 1 | 2020 | 128 | 0.690 |
Why?
|
| Cardiac Valve Annuloplasty | 2 | 2023 | 14 | 0.680 |
Why?
|
| Fontan Procedure | 1 | 2020 | 56 | 0.680 |
Why?
|
| Cardiomyopathies | 5 | 2017 | 267 | 0.670 |
Why?
|
| Primary Graft Dysfunction | 1 | 2020 | 41 | 0.670 |
Why?
|
| Atrial Fibrillation | 4 | 2019 | 357 | 0.660 |
Why?
|
| Seasons | 1 | 2020 | 240 | 0.640 |
Why?
|
| Patient Readmission | 7 | 2020 | 355 | 0.620 |
Why?
|
| Survival Rate | 13 | 2022 | 1899 | 0.600 |
Why?
|
| Sex Characteristics | 1 | 2020 | 328 | 0.600 |
Why?
|
| Thromboembolism | 4 | 2019 | 122 | 0.590 |
Why?
|
| Monitoring, Intraoperative | 3 | 2015 | 109 | 0.590 |
Why?
|
| Cardiotonic Agents | 4 | 2019 | 90 | 0.590 |
Why?
|
| Cardioplegic Solutions | 7 | 2020 | 17 | 0.580 |
Why?
|
| Ventricular Dysfunction, Right | 4 | 2020 | 145 | 0.580 |
Why?
|
| Smoking Cessation | 1 | 2020 | 258 | 0.570 |
Why?
|
| Warm Ischemia | 2 | 2023 | 32 | 0.570 |
Why?
|
| Tissue and Organ Procurement | 5 | 2024 | 360 | 0.560 |
Why?
|
| Atrial Flutter | 1 | 2017 | 36 | 0.560 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2017 | 23 | 0.550 |
Why?
|
| Atrial Remodeling | 1 | 2017 | 24 | 0.550 |
Why?
|
| Smoking | 1 | 2020 | 625 | 0.530 |
Why?
|
| Coronary Vessels | 9 | 2018 | 194 | 0.530 |
Why?
|
| Graft Rejection | 13 | 2021 | 1076 | 0.520 |
Why?
|
| Vascular Surgical Procedures | 2 | 2015 | 149 | 0.520 |
Why?
|
| Proportional Hazards Models | 10 | 2020 | 848 | 0.520 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 451 | 0.500 |
Why?
|
| Pulmonary Artery | 3 | 2020 | 323 | 0.500 |
Why?
|
| Risk Factors | 21 | 2024 | 5562 | 0.500 |
Why?
|
| Solutions | 5 | 1992 | 86 | 0.490 |
Why?
|
| Blood Transfusion, Autologous | 2 | 2018 | 16 | 0.480 |
Why?
|
| Severity of Illness Index | 12 | 2020 | 1863 | 0.470 |
Why?
|
| Device Removal | 4 | 2020 | 168 | 0.460 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2013 | 16 | 0.440 |
Why?
|
| Myocardial Contraction | 8 | 2010 | 252 | 0.430 |
Why?
|
| Heart Valve Diseases | 5 | 2018 | 116 | 0.420 |
Why?
|
| Stroke Volume | 5 | 2022 | 479 | 0.420 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2007 | 58 | 0.420 |
Why?
|
| Ambulatory Care | 3 | 2018 | 186 | 0.410 |
Why?
|
| Pacemaker, Artificial | 3 | 2020 | 96 | 0.400 |
Why?
|
| Sternum | 5 | 2007 | 35 | 0.400 |
Why?
|
| Central Venous Pressure | 4 | 2020 | 26 | 0.400 |
Why?
|
| Ventricular Function, Right | 5 | 2020 | 150 | 0.390 |
Why?
|
| Arterial Pressure | 4 | 2020 | 38 | 0.390 |
Why?
|
| Donor Selection | 2 | 2024 | 77 | 0.380 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2018 | 101 | 0.380 |
Why?
|
| Heart Valve Prosthesis | 3 | 2023 | 98 | 0.380 |
Why?
|
| Hemolysis | 3 | 2020 | 64 | 0.380 |
Why?
|
| Waiting Lists | 4 | 2024 | 187 | 0.380 |
Why?
|
| Chordae Tendineae | 3 | 2015 | 23 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2019 | 855 | 0.380 |
Why?
|
| Aortic Valve Stenosis | 4 | 2023 | 146 | 0.370 |
Why?
|
| Anticoagulants | 9 | 2023 | 432 | 0.370 |
Why?
|
| Aortic Rupture | 2 | 2022 | 57 | 0.360 |
Why?
|
| Heart Neoplasms | 3 | 2002 | 63 | 0.360 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2018 | 200 | 0.360 |
Why?
|
| Cardiopulmonary Bypass | 5 | 2014 | 160 | 0.360 |
Why?
|
| United States | 16 | 2024 | 7114 | 0.360 |
Why?
|
| Thoracotomy | 3 | 2007 | 64 | 0.360 |
Why?
|
| Triiodothyronine | 4 | 1997 | 346 | 0.350 |
Why?
|
| Risk Assessment | 10 | 2018 | 2327 | 0.350 |
Why?
|
| Cold Ischemia | 1 | 2010 | 19 | 0.350 |
Why?
|
| Patient Selection | 4 | 2020 | 682 | 0.340 |
Why?
|
| Coronary Artery Disease | 5 | 2020 | 367 | 0.340 |
Why?
|
| Shock, Cardiogenic | 6 | 2021 | 119 | 0.340 |
Why?
|
| Feasibility Studies | 8 | 2020 | 785 | 0.340 |
Why?
|
| Glutamine | 2 | 2007 | 79 | 0.340 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 73 | 0.340 |
Why?
|
| Coronary Aneurysm | 2 | 2007 | 16 | 0.340 |
Why?
|
| Hypoalbuminemia | 2 | 2020 | 9 | 0.320 |
Why?
|
| Pheochromocytoma | 2 | 2002 | 49 | 0.320 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 51 | 0.320 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 716 | 0.310 |
Why?
|
| Catheterization | 1 | 2010 | 237 | 0.310 |
Why?
|
| Prognosis | 10 | 2022 | 3800 | 0.310 |
Why?
|
| Robotics | 2 | 2018 | 270 | 0.310 |
Why?
|
| Cohort Studies | 10 | 2022 | 2887 | 0.310 |
Why?
|
| Heart Defects, Congenital | 2 | 2021 | 365 | 0.300 |
Why?
|
| Troponin I | 1 | 2008 | 26 | 0.300 |
Why?
|
| Kidney Transplantation | 4 | 2022 | 856 | 0.300 |
Why?
|
| Endoscopy | 2 | 2018 | 352 | 0.300 |
Why?
|
| Tachycardia, Ventricular | 2 | 2020 | 124 | 0.300 |
Why?
|
| Preoperative Care | 4 | 2015 | 395 | 0.300 |
Why?
|
| Exercise Tolerance | 2 | 2020 | 55 | 0.300 |
Why?
|
| Recovery of Function | 5 | 2020 | 301 | 0.290 |
Why?
|
| Suture Techniques | 4 | 2023 | 144 | 0.290 |
Why?
|
| Quality of Life | 5 | 2021 | 1682 | 0.290 |
Why?
|
| Heart Atria | 6 | 2020 | 282 | 0.290 |
Why?
|
| Marfan Syndrome | 1 | 2007 | 28 | 0.280 |
Why?
|
| Prosthesis Failure | 4 | 2020 | 117 | 0.270 |
Why?
|
| Myocytes, Cardiac | 3 | 2004 | 314 | 0.270 |
Why?
|
| Hemostatics | 2 | 1997 | 58 | 0.260 |
Why?
|
| Predictive Value of Tests | 11 | 2021 | 1732 | 0.260 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2006 | 6 | 0.260 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 97 | 0.260 |
Why?
|
| Hemoglobins | 3 | 2018 | 193 | 0.260 |
Why?
|
| Pericardium | 3 | 2018 | 70 | 0.260 |
Why?
|
| Glutathione | 9 | 2003 | 108 | 0.250 |
Why?
|
| Prosthesis-Related Infections | 2 | 2014 | 61 | 0.250 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 41 | 0.250 |
Why?
|
| Chicago | 6 | 2020 | 1434 | 0.250 |
Why?
|
| Myocardial Reperfusion | 2 | 2003 | 28 | 0.250 |
Why?
|
| Assisted Circulation | 2 | 2018 | 16 | 0.240 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 6787 | 0.240 |
Why?
|
| Postoperative Period | 3 | 2021 | 301 | 0.240 |
Why?
|
| Echocardiography, Doppler, Color | 7 | 2015 | 103 | 0.240 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 2658 | 0.240 |
Why?
|
| Survival Analysis | 8 | 2018 | 1497 | 0.240 |
Why?
|
| Warfarin | 2 | 2023 | 104 | 0.230 |
Why?
|
| Treatment Failure | 2 | 2020 | 278 | 0.230 |
Why?
|
| Polytetrafluoroethylene | 2 | 2022 | 74 | 0.230 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2015 | 332 | 0.220 |
Why?
|
| Internal Fixators | 1 | 2003 | 15 | 0.220 |
Why?
|
| Organ Size | 3 | 2021 | 372 | 0.220 |
Why?
|
| CD11b Antigen | 1 | 2003 | 36 | 0.220 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 25 | 0.220 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 696 | 0.220 |
Why?
|
| Electrocardiography | 6 | 2021 | 497 | 0.210 |
Why?
|
| Mathematical Concepts | 2 | 2020 | 19 | 0.210 |
Why?
|
| Signal Transduction | 3 | 2012 | 3404 | 0.210 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1704 | 0.210 |
Why?
|
| Blood Coagulation | 3 | 2023 | 91 | 0.210 |
Why?
|
| Sternotomy | 2 | 2022 | 24 | 0.210 |
Why?
|
| Monocytes | 2 | 2003 | 221 | 0.210 |
Why?
|
| Thoracic Surgery | 1 | 2023 | 47 | 0.210 |
Why?
|
| Catheter Ablation | 3 | 2020 | 254 | 0.200 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2021 | 164 | 0.200 |
Why?
|
| Intraoperative Period | 4 | 2014 | 91 | 0.200 |
Why?
|
| Heart Rate | 3 | 2022 | 498 | 0.200 |
Why?
|
| Sensitivity and Specificity | 7 | 2015 | 2018 | 0.200 |
Why?
|
| Lactic Acid | 2 | 2021 | 93 | 0.200 |
Why?
|
| Ventricular Remodeling | 2 | 2021 | 108 | 0.190 |
Why?
|
| Myocardial Ischemia | 3 | 2017 | 164 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2023 | 242 | 0.190 |
Why?
|
| Blood Flow Velocity | 2 | 2019 | 200 | 0.190 |
Why?
|
| Ischemia | 1 | 2023 | 253 | 0.190 |
Why?
|
| Recurrence | 6 | 2018 | 1147 | 0.190 |
Why?
|
| Mitral Valve Stenosis | 1 | 2021 | 38 | 0.190 |
Why?
|
| Aortic Coarctation | 1 | 2021 | 36 | 0.190 |
Why?
|
| Decision Making | 3 | 2020 | 671 | 0.190 |
Why?
|
| Vasodilator Agents | 5 | 2011 | 145 | 0.190 |
Why?
|
| Cause of Death | 3 | 2018 | 269 | 0.180 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 96 | 0.180 |
Why?
|
| Benchmarking | 1 | 2021 | 79 | 0.180 |
Why?
|
| Coronary Sinus | 1 | 2020 | 8 | 0.180 |
Why?
|
| Perioperative Period | 1 | 2020 | 25 | 0.180 |
Why?
|
| Nutrition Therapy | 1 | 2020 | 10 | 0.180 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 2 | 2011 | 22 | 0.180 |
Why?
|
| Dobutamine | 1 | 2000 | 61 | 0.180 |
Why?
|
| Coronary Stenosis | 1 | 2020 | 39 | 0.180 |
Why?
|
| Situs Inversus | 1 | 2020 | 15 | 0.180 |
Why?
|
| Carotid Artery, Internal | 1 | 2020 | 69 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 39 | 0.180 |
Why?
|
| Aspirin | 1 | 2021 | 162 | 0.170 |
Why?
|
| Disease-Free Survival | 6 | 2019 | 1169 | 0.170 |
Why?
|
| Endarterectomy, Carotid | 1 | 2020 | 74 | 0.170 |
Why?
|
| Adenosine | 8 | 2003 | 240 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 91 | 0.170 |
Why?
|
| Organizational Policy | 1 | 2020 | 55 | 0.170 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 27 | 0.170 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 105 | 0.170 |
Why?
|
| Lung Transplantation | 2 | 2022 | 313 | 0.170 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.170 |
Why?
|
| Registries | 2 | 2021 | 808 | 0.170 |
Why?
|
| Smokers | 1 | 2020 | 46 | 0.170 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 44 | 0.170 |
Why?
|
| Abnormalities, Multiple | 1 | 2021 | 234 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 117 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 58 | 0.170 |
Why?
|
| Aorta | 3 | 2021 | 289 | 0.170 |
Why?
|
| Electric Impedance | 1 | 2020 | 111 | 0.160 |
Why?
|
| Health Resources | 1 | 2020 | 80 | 0.160 |
Why?
|
| Antilymphocyte Serum | 2 | 1996 | 70 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 131 | 0.160 |
Why?
|
| Allografts | 1 | 2020 | 184 | 0.160 |
Why?
|
| Energy Metabolism | 2 | 2019 | 282 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 105 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 55 | 0.160 |
Why?
|
| Raffinose | 7 | 1994 | 23 | 0.160 |
Why?
|
| Pneumonia, Aspiration | 1 | 2018 | 19 | 0.160 |
Why?
|
| Heart Function Tests | 1 | 2018 | 33 | 0.160 |
Why?
|
| Biomarkers | 5 | 2018 | 1778 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 124 | 0.160 |
Why?
|
| Neuromuscular Blockade | 1 | 2018 | 26 | 0.160 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2018 | 28 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2020 | 230 | 0.160 |
Why?
|
| Allopurinol | 7 | 1994 | 77 | 0.160 |
Why?
|
| Atrial Appendage | 1 | 2018 | 33 | 0.150 |
Why?
|
| Cicatrix | 1 | 2018 | 68 | 0.150 |
Why?
|
| Oxidative Stress | 3 | 2019 | 458 | 0.150 |
Why?
|
| Age Factors | 3 | 2018 | 1880 | 0.150 |
Why?
|
| Anastomosis, Surgical | 3 | 2018 | 277 | 0.150 |
Why?
|
| Enoxaparin | 1 | 2018 | 23 | 0.150 |
Why?
|
| Testosterone | 1 | 2019 | 272 | 0.150 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 317 | 0.150 |
Why?
|
| Octreotide | 1 | 2018 | 28 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 182 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 166 | 0.150 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 42 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2018 | 124 | 0.140 |
Why?
|
| Nitric Oxide | 3 | 2010 | 280 | 0.140 |
Why?
|
| Hospitalization | 2 | 2022 | 888 | 0.140 |
Why?
|
| Heart Septum | 2 | 2008 | 47 | 0.140 |
Why?
|
| Cardiomegaly | 4 | 2012 | 120 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2019 | 353 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 1255 | 0.140 |
Why?
|
| Equipment Failure | 4 | 2018 | 122 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 159 | 0.140 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2017 | 54 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 128 | 0.140 |
Why?
|
| Magnets | 1 | 2017 | 14 | 0.140 |
Why?
|
| Equipment Design | 6 | 2018 | 422 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 281 | 0.140 |
Why?
|
| Tachycardia | 1 | 2017 | 37 | 0.140 |
Why?
|
| Vitamin K | 1 | 1997 | 25 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2018 | 171 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2016 | 258 | 0.140 |
Why?
|
| Aprotinin | 1 | 1996 | 26 | 0.140 |
Why?
|
| Fibrinolysis | 1 | 1996 | 37 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 91 | 0.130 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 17 | 0.130 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1996 | 103 | 0.130 |
Why?
|
| Atrial Function | 1 | 1996 | 19 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 257 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 290 | 0.130 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 27 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 366 | 0.130 |
Why?
|
| Animals | 23 | 2019 | 27536 | 0.130 |
Why?
|
| Isoantibodies | 1 | 1996 | 120 | 0.130 |
Why?
|
| Mitochondria | 1 | 2019 | 556 | 0.130 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 30 | 0.130 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 66 | 0.120 |
Why?
|
| HLA Antigens | 1 | 1996 | 227 | 0.120 |
Why?
|
| Heart Arrest | 2 | 2016 | 278 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.120 |
Why?
|
| Sodium-Calcium Exchanger | 3 | 1999 | 22 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 744 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2015 | 158 | 0.120 |
Why?
|
| Kidney Diseases | 2 | 2008 | 320 | 0.120 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2014 | 19 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 414 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2017 | 275 | 0.120 |
Why?
|
| Blood Pressure | 5 | 2018 | 906 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2018 | 2770 | 0.120 |
Why?
|
| Posture | 1 | 2014 | 125 | 0.110 |
Why?
|
| Veins | 1 | 2014 | 95 | 0.110 |
Why?
|
| Electrodes, Implanted | 2 | 2014 | 185 | 0.110 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 60 | 0.110 |
Why?
|
| Coronary Angiography | 4 | 2016 | 244 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 354 | 0.110 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 72 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.110 |
Why?
|
| T-Lymphocytes | 5 | 2003 | 1221 | 0.110 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 110 | 0.110 |
Why?
|
| Adolescent | 8 | 2019 | 9347 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 700 | 0.110 |
Why?
|
| Insulin | 7 | 1994 | 1148 | 0.110 |
Why?
|
| Patient Safety | 1 | 2016 | 219 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2017 | 584 | 0.110 |
Why?
|
| Septal Occluder Device | 4 | 2015 | 45 | 0.110 |
Why?
|
| Endocardium | 4 | 2000 | 98 | 0.110 |
Why?
|
| Illinois | 3 | 2019 | 485 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 983 | 0.100 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1992 | 27 | 0.100 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.100 |
Why?
|
| Immunosuppressive Agents | 4 | 2017 | 979 | 0.100 |
Why?
|
| Chronic Disease | 5 | 2010 | 958 | 0.100 |
Why?
|
| Balloon Occlusion | 1 | 2012 | 29 | 0.100 |
Why?
|
| Sirtuins | 1 | 2012 | 46 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1992 | 54 | 0.100 |
Why?
|
| Hypertension | 1 | 2018 | 747 | 0.100 |
Why?
|
| Potassium Compounds | 1 | 1992 | 3 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 112 | 0.100 |
Why?
|
| Cystatin C | 2 | 2010 | 27 | 0.100 |
Why?
|
| Physicians | 1 | 2019 | 692 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2018 | 147 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2012 | 244 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2018 | 780 | 0.090 |
Why?
|
| Acetylcholine | 2 | 2002 | 177 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2012 | 109 | 0.090 |
Why?
|
| Coronary Circulation | 3 | 2007 | 131 | 0.090 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 359 | 0.090 |
Why?
|
| Mitral Valve Prolapse | 1 | 2011 | 24 | 0.090 |
Why?
|
| International Normalized Ratio | 2 | 2023 | 39 | 0.090 |
Why?
|
| Sirtuin 3 | 1 | 2010 | 30 | 0.090 |
Why?
|
| Mitochondria, Heart | 1 | 2010 | 50 | 0.090 |
Why?
|
| Vena Cava, Superior | 2 | 2020 | 60 | 0.090 |
Why?
|
| Cell Death | 4 | 2004 | 261 | 0.090 |
Why?
|
| Sheep | 2 | 2007 | 251 | 0.090 |
Why?
|
| Prostheses and Implants | 2 | 2006 | 125 | 0.090 |
Why?
|
| Surgical Wound Infection | 2 | 2004 | 204 | 0.090 |
Why?
|
| Biopsy | 3 | 2000 | 1184 | 0.090 |
Why?
|
| Heart, Artificial | 1 | 2009 | 9 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 86 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 60 | 0.080 |
Why?
|
| Graft Survival | 5 | 2021 | 908 | 0.080 |
Why?
|
| Cardiac Output, Low | 2 | 1999 | 14 | 0.080 |
Why?
|
| Thrombin | 3 | 2016 | 61 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2012 | 227 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 294 | 0.080 |
Why?
|
| Extracorporeal Circulation | 2 | 2022 | 37 | 0.080 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2003 | 65 | 0.080 |
Why?
|
| Papio | 4 | 1993 | 82 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 1237 | 0.080 |
Why?
|
| Materials Testing | 2 | 2019 | 93 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 521 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2010 | 234 | 0.080 |
Why?
|
| Child | 5 | 2021 | 7242 | 0.070 |
Why?
|
| Comorbidity | 3 | 2019 | 953 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2010 | 468 | 0.070 |
Why?
|
| Young Adult | 5 | 2021 | 6418 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2011 | 759 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 101 | 0.070 |
Why?
|
| Drainage | 2 | 2020 | 165 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 657 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2017 | 682 | 0.070 |
Why?
|
| Cytodiagnosis | 1 | 1987 | 46 | 0.070 |
Why?
|
| Stents | 2 | 2001 | 412 | 0.070 |
Why?
|
| Brain Death | 3 | 2010 | 83 | 0.070 |
Why?
|
| Saphenous Vein | 2 | 1997 | 61 | 0.070 |
Why?
|
| Exercise Test | 2 | 2019 | 166 | 0.070 |
Why?
|
| Heparin | 3 | 2019 | 185 | 0.070 |
Why?
|
| Ischemic Preconditioning, Myocardial | 2 | 2003 | 12 | 0.070 |
Why?
|
| Mammary Arteries | 2 | 1997 | 34 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 1997 | 241 | 0.070 |
Why?
|
| Transplantation, Homologous | 4 | 2021 | 995 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1913 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 60 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 1987 | 129 | 0.070 |
Why?
|
| Reference Values | 2 | 2018 | 662 | 0.070 |
Why?
|
| Cyclosporine | 3 | 1998 | 238 | 0.070 |
Why?
|
| Chick Embryo | 2 | 2003 | 230 | 0.070 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2005 | 5 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 865 | 0.070 |
Why?
|
| Body Constitution | 2 | 1996 | 26 | 0.060 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 98 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2001 | 100 | 0.060 |
Why?
|
| Models, Animal | 1 | 2007 | 277 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2016 | 296 | 0.060 |
Why?
|
| Blood Transfusion | 2 | 1997 | 171 | 0.060 |
Why?
|
| Emergencies | 1 | 2006 | 122 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 385 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 2395 | 0.060 |
Why?
|
| Biomechanical Phenomena | 1 | 2007 | 477 | 0.060 |
Why?
|
| Creatinine | 2 | 2014 | 294 | 0.060 |
Why?
|
| Disease Progression | 2 | 2020 | 1469 | 0.060 |
Why?
|
| Rats | 3 | 2007 | 4048 | 0.060 |
Why?
|
| Sex Factors | 2 | 2018 | 1075 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2020 | 3773 | 0.060 |
Why?
|
| Mediastinitis | 1 | 2004 | 14 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 51 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2004 | 36 | 0.060 |
Why?
|
| Bone Plates | 1 | 2004 | 27 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1929 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2004 | 115 | 0.060 |
Why?
|
| Pain, Postoperative | 1 | 2007 | 257 | 0.060 |
Why?
|
| Observer Variation | 2 | 2016 | 614 | 0.060 |
Why?
|
| Guanidines | 1 | 2003 | 31 | 0.060 |
Why?
|
| Sulfones | 1 | 2003 | 45 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 68 | 0.050 |
Why?
|
| Phenprocoumon | 1 | 2023 | 1 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2019 | 408 | 0.050 |
Why?
|
| Myosin Heavy Chains | 1 | 2003 | 92 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2004 | 315 | 0.050 |
Why?
|
| DNA, Single-Stranded | 1 | 2003 | 93 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 1987 | 572 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 1243 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 1055 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 77 | 0.050 |
Why?
|
| Cell Hypoxia | 1 | 2003 | 173 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2003 | 154 | 0.050 |
Why?
|
| Length of Stay | 2 | 2019 | 749 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 304 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1579 | 0.050 |
Why?
|
| Sarcoplasmic Reticulum | 2 | 1999 | 25 | 0.050 |
Why?
|
| Tiopronin | 1 | 2002 | 6 | 0.050 |
Why?
|
| Fibroma | 1 | 2002 | 33 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 1998 | 416 | 0.050 |
Why?
|
| Free Radicals | 1 | 2002 | 71 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2017 | 253 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 48 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2010 | 665 | 0.050 |
Why?
|
| Platelet Factor 4 | 3 | 1996 | 12 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 149 | 0.050 |
Why?
|
| Image Enhancement | 2 | 2015 | 565 | 0.050 |
Why?
|
| Electric Countershock | 2 | 1992 | 55 | 0.050 |
Why?
|
| Cyclic AMP | 2 | 2011 | 277 | 0.050 |
Why?
|
| ABO Blood-Group System | 1 | 2021 | 58 | 0.050 |
Why?
|
| Disaccharides | 1 | 2001 | 23 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 168 | 0.050 |
Why?
|
| Electrolytes | 1 | 2001 | 52 | 0.050 |
Why?
|
| Protective Agents | 1 | 2001 | 34 | 0.050 |
Why?
|
| Platelet Count | 3 | 1996 | 93 | 0.050 |
Why?
|
| Perfusion | 1 | 2022 | 253 | 0.050 |
Why?
|
| Mannitol | 1 | 2001 | 50 | 0.050 |
Why?
|
| Histidine | 1 | 2001 | 56 | 0.050 |
Why?
|
| In Vitro Techniques | 3 | 1999 | 996 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 366 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2003 | 395 | 0.050 |
Why?
|
| Glutamates | 1 | 2001 | 88 | 0.050 |
Why?
|
| Action Potentials | 3 | 2018 | 601 | 0.050 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2001 | 41 | 0.050 |
Why?
|
| Bilirubin | 1 | 2021 | 131 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2021 | 69 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2001 | 70 | 0.050 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2000 | 8 | 0.050 |
Why?
|
| Foreign-Body Migration | 1 | 2001 | 39 | 0.050 |
Why?
|
| Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 44 | 0.040 |
Why?
|
| Heart Arrest, Induced | 1 | 2020 | 29 | 0.040 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2000 | 16 | 0.040 |
Why?
|
| Calcium Channels, L-Type | 1 | 2000 | 38 | 0.040 |
Why?
|
| Radiography, Thoracic | 2 | 2018 | 324 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2001 | 267 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2001 | 105 | 0.040 |
Why?
|
| Anesthesia | 1 | 2002 | 169 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 28 | 0.040 |
Why?
|
| Apoptosis | 2 | 2010 | 1718 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Vasoconstriction | 2 | 1997 | 92 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 59 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 2020 | 108 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2021 | 171 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2000 | 99 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 1534 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 23 | 0.040 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 9 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lipocalin-2 | 2 | 2010 | 37 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 142 | 0.040 |
Why?
|
| Lipocalins | 2 | 2010 | 35 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 49 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2002 | 346 | 0.040 |
Why?
|
| Acute-Phase Proteins | 2 | 2010 | 37 | 0.040 |
Why?
|
| Platelet Aggregation | 2 | 1996 | 44 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 75 | 0.040 |
Why?
|
| Ventricular Function | 1 | 1999 | 53 | 0.040 |
Why?
|
| Thromboxane B2 | 2 | 1996 | 11 | 0.040 |
Why?
|
| Calcium | 3 | 1999 | 1179 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2001 | 257 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 50 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 117 | 0.040 |
Why?
|
| Atracurium | 1 | 2018 | 5 | 0.040 |
Why?
|
| Epicardial Mapping | 1 | 2018 | 10 | 0.040 |
Why?
|
| Succinylcholine | 1 | 2018 | 14 | 0.040 |
Why?
|
| Photopheresis | 1 | 1998 | 12 | 0.040 |
Why?
|
| Sinoatrial Node | 2 | 1996 | 12 | 0.040 |
Why?
|
| Postoperative Care | 3 | 1995 | 232 | 0.040 |
Why?
|
| Cell Line | 1 | 2003 | 2495 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 115 | 0.040 |
Why?
|
| Vasodilation | 2 | 1997 | 93 | 0.040 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2004 | 37 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2019 | 2016 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 6 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2000 | 276 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 289 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 147 | 0.040 |
Why?
|
| Creatine Kinase | 2 | 2003 | 52 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 32 | 0.040 |
Why?
|
| ROC Curve | 2 | 2011 | 778 | 0.040 |
Why?
|
| Surgical Staplers | 1 | 2018 | 11 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 1998 | 50 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 64 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1998 | 72 | 0.040 |
Why?
|
| Walk Test | 1 | 2018 | 24 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2011 | 899 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2019 | 286 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 110 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2018 | 196 | 0.040 |
Why?
|
| Software | 2 | 2013 | 669 | 0.040 |
Why?
|
| Thyroxine | 1 | 2019 | 355 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2018 | 129 | 0.040 |
Why?
|
| Neutropenia | 1 | 2018 | 214 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 866 | 0.040 |
Why?
|
| Hypothyroidism | 1 | 2019 | 243 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1868 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1082 | 0.040 |
Why?
|
| Pneumonia | 1 | 2018 | 183 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 1997 | 35 | 0.030 |
Why?
|
| Liver | 1 | 2022 | 1211 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1997 | 105 | 0.030 |
Why?
|
| Bradycardia | 1 | 1996 | 40 | 0.030 |
Why?
|
| Chest Tubes | 1 | 1996 | 24 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 1996 | 137 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 33 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 69 | 0.030 |
Why?
|
| Contraindications | 1 | 2016 | 70 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 174 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 1996 | 117 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 45 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1292 | 0.030 |
Why?
|
| Methylmethacrylates | 1 | 1995 | 8 | 0.030 |
Why?
|
| Bone Cements | 1 | 1995 | 9 | 0.030 |
Why?
|
| Arrhythmia, Sinus | 1 | 1995 | 7 | 0.030 |
Why?
|
| Aminophylline | 1 | 1995 | 14 | 0.030 |
Why?
|
| Potassium | 2 | 1997 | 258 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 11858 | 0.030 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1994 | 11 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 1983 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 277 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 3189 | 0.030 |
Why?
|
| Fibromuscular Dysplasia | 1 | 1994 | 11 | 0.030 |
Why?
|
| Fibrin Tissue Adhesive | 2 | 1992 | 15 | 0.030 |
Why?
|
| Stomach | 1 | 2015 | 111 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 432 | 0.030 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2014 | 19 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 70 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 85 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1997 | 222 | 0.030 |
Why?
|
| Iloprost | 1 | 1993 | 15 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 1993 | 43 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 1993 | 62 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 1993 | 30 | 0.030 |
Why?
|
| Critical Illness | 2 | 2012 | 311 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 464 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2013 | 51 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 1995 | 318 | 0.030 |
Why?
|
| Postpartum Period | 1 | 1994 | 153 | 0.030 |
Why?
|
| New York City | 1 | 1992 | 61 | 0.030 |
Why?
|
| Coronary Disease | 1 | 1994 | 260 | 0.030 |
Why?
|
| Histone Demethylases | 1 | 2012 | 32 | 0.030 |
Why?
|
| Acetylation | 1 | 2012 | 132 | 0.030 |
Why?
|
| Adhesives | 1 | 1992 | 5 | 0.030 |
Why?
|
| Enzyme Inhibitors | 3 | 2001 | 644 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3253 | 0.020 |
Why?
|
| Dopamine | 1 | 1993 | 276 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 114 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2012 | 94 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 1992 | 25 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 2003 | 1158 | 0.020 |
Why?
|
| Lasers | 1 | 1992 | 107 | 0.020 |
Why?
|
| Models, Economic | 1 | 2012 | 62 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 1991 | 75 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1993 | 148 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2011 | 66 | 0.020 |
Why?
|
| Esophagus | 1 | 1992 | 107 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1992 | 150 | 0.020 |
Why?
|
| Diastole | 1 | 1991 | 142 | 0.020 |
Why?
|
| Cold Temperature | 1 | 1991 | 160 | 0.020 |
Why?
|
| Critical Care | 1 | 1994 | 384 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 103 | 0.020 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1731 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1994 | 380 | 0.020 |
Why?
|
| CD3 Complex | 2 | 2001 | 134 | 0.020 |
Why?
|
| Bronchi | 1 | 1992 | 230 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2011 | 252 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2010 | 75 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 305 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 112 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 84 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1606 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 88 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 126 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 162 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 338 | 0.020 |
Why?
|
| Chromatin | 1 | 2012 | 404 | 0.020 |
Why?
|
| Cytosol | 2 | 2001 | 193 | 0.020 |
Why?
|
| Wound Healing | 1 | 1992 | 362 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 467 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 961 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2012 | 326 | 0.020 |
Why?
|
| Thapsigargin | 2 | 1999 | 55 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 227 | 0.020 |
Why?
|
| Isoproterenol | 2 | 1999 | 62 | 0.020 |
Why?
|
| Calcium-Transporting ATPases | 2 | 1999 | 29 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2010 | 264 | 0.020 |
Why?
|
| Computer Systems | 1 | 2008 | 79 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 2 | 1999 | 74 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2008 | 91 | 0.020 |
Why?
|
| Cell Movement | 2 | 2003 | 787 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1214 | 0.020 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2007 | 9 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 2 | 2003 | 511 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 490 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 649 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 93 | 0.020 |
Why?
|
| Electric Stimulation | 2 | 1999 | 365 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2003 | 2026 | 0.020 |
Why?
|
| Swine | 2 | 2003 | 590 | 0.020 |
Why?
|
| Dogs | 3 | 1993 | 706 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2008 | 129 | 0.020 |
Why?
|
| Base Sequence | 2 | 2001 | 2329 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1987 | 160 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 3024 | 0.020 |
Why?
|
| Electrophysiology | 2 | 1998 | 403 | 0.020 |
Why?
|
| Isotonic Solutions | 2 | 1997 | 17 | 0.020 |
Why?
|
| Factor XIII | 1 | 1985 | 5 | 0.020 |
Why?
|
| Fibrinogen | 1 | 1985 | 53 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 1985 | 23 | 0.020 |
Why?
|
| Caspases | 1 | 2004 | 155 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 308 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2677 | 0.010 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2003 | 23 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2003 | 56 | 0.010 |
Why?
|
| NAD | 1 | 2003 | 72 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2003 | 24 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 146 | 0.010 |
Why?
|
| Alanine | 1 | 2003 | 84 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 238 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 217 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1227 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 63 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 107 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 274 | 0.010 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 130 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1998 | 2887 | 0.010 |
Why?
|
| Rabbits | 2 | 1995 | 640 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 316 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 183 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 645 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2003 | 515 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 793 | 0.010 |
Why?
|
| Chickens | 1 | 2002 | 212 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2001 | 45 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 244 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2001 | 32 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2001 | 49 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2001 | 63 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 389 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 122 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 126 | 0.010 |
Why?
|
| fas Receptor | 1 | 2001 | 77 | 0.010 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2000 | 17 | 0.010 |
Why?
|
| Glucose | 1 | 2003 | 629 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 1122 | 0.010 |
Why?
|
| Phlebography | 1 | 2000 | 69 | 0.010 |
Why?
|
| Clone Cells | 1 | 2000 | 214 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 178 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 194 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2000 | 93 | 0.010 |
Why?
|
| Thiourea | 1 | 1999 | 9 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2001 | 466 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2000 | 278 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1801 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1998 | 120 | 0.010 |
Why?
|
| Hypoxia | 1 | 2003 | 657 | 0.010 |
Why?
|
| Patch-Clamp Techniques | 1 | 1999 | 397 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 1998 | 31 | 0.010 |
Why?
|
| Biological Availability | 1 | 1998 | 91 | 0.010 |
Why?
|
| Nifedipine | 1 | 1998 | 26 | 0.010 |
Why?
|
| Caffeine | 1 | 1999 | 83 | 0.010 |
Why?
|
| Temperature | 1 | 1999 | 409 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1998 | 150 | 0.010 |
Why?
|
| Macrophages | 1 | 2001 | 582 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 121 | 0.010 |
Why?
|
| Reaction Time | 1 | 1999 | 311 | 0.010 |
Why?
|
| Vasomotor System | 1 | 1997 | 13 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1997 | 36 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 1311 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1997 | 39 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 1997 | 42 | 0.010 |
Why?
|
| Propranolol | 1 | 1997 | 44 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 543 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 1997 | 53 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 303 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1997 | 56 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1998 | 245 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 667 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2064 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2003 | 1380 | 0.010 |
Why?
|
| Sodium | 1 | 1998 | 333 | 0.010 |
Why?
|
| Indoles | 1 | 1998 | 301 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1998 | 602 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 919 | 0.010 |
Why?
|
| Philadelphia | 1 | 1995 | 18 | 0.010 |
Why?
|
| Methylmethacrylate | 1 | 1995 | 6 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 1665 | 0.010 |
Why?
|
| Body Surface Potential Mapping | 1 | 1994 | 25 | 0.010 |
Why?
|
| Atrioventricular Node | 1 | 1994 | 35 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1994 | 43 | 0.010 |
Why?
|
| Bundle of His | 1 | 1994 | 46 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2000 | 1533 | 0.010 |
Why?
|
| beta-Thromboglobulin | 1 | 1993 | 1 | 0.010 |
Why?
|
| Fibrinopeptide A | 1 | 1993 | 3 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1993 | 46 | 0.010 |
Why?
|
| Heart Conduction System | 1 | 1994 | 112 | 0.010 |
Why?
|
| Platelet Activation | 1 | 1993 | 14 | 0.010 |
Why?
|
| Pancreatic Elastase | 1 | 1993 | 15 | 0.010 |
Why?
|
| Leukocyte Elastase | 1 | 1993 | 8 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1993 | 224 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 435 | 0.010 |
Why?
|
| Platelet Adhesiveness | 1 | 1992 | 8 | 0.010 |
Why?
|
| Tensile Strength | 1 | 1992 | 82 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 270 | 0.010 |
Why?
|
| Surface Properties | 1 | 1992 | 131 | 0.010 |
Why?
|
| Random Allocation | 1 | 1992 | 327 | 0.010 |
Why?
|
| Azathioprine | 1 | 1992 | 124 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 846 | 0.010 |
Why?
|
| Prednisone | 1 | 1992 | 255 | 0.010 |
Why?
|
| Epithelium | 1 | 1992 | 323 | 0.010 |
Why?
|
| Fibrosis | 1 | 1991 | 236 | 0.010 |
Why?
|
| Chemical Precipitation | 1 | 1985 | 18 | 0.000 |
Why?
|
| Cryoprotective Agents | 1 | 1985 | 9 | 0.000 |
Why?
|
| Freezing | 1 | 1985 | 33 | 0.000 |
Why?
|
| Plasma | 1 | 1985 | 51 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1985 | 203 | 0.000 |
Why?
|